Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates.

Berruti, A; Dogliotti, L; Tucci, M; Tarabuzzi, R; Fontana, D; Angeli, A

Berruti, A; Dogliotti, L; Tucci, M; Tarabuzzi, R; Fontana, D; Angeli, A.

Affiliation

Berruti A; Department of Clinical Science and Biology, Università degli Studi di Torino, Torino, Italy.

J Urol ; 166(6): 2023-31, 2001 Dec.

Article in En | MEDLINE | ID: mdl-11696699

Subject(s)

Bone Neoplasms/metabolism; Bone Neoplasms/secondary; Diphosphonates/therapeutic use; Prostatic Neoplasms/pathology; Bone Neoplasms/physiopathology; Bone Remodeling; Clinical Trials as Topic; Diphosphonates/pharmacology; Humans; Male; Metabolic Diseases/etiology; Pain/drug therapy

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Prostatic Neoplasms / Bone Neoplasms / Diphosphonates Type of study: Clinical_trials / Etiology_studies / Prognostic_studies Limits: Humans / Male Language: En Year: 2001 Type: Article

Search on Google

XML

PubMed Links